Off-Label Use Potential With J&J’s Xarelto Not A Factor In Review, FDA Says
Executive Summary
In reviewing the approvability of Johnson & Johnson's factor Xa inhibitorXarelto (rivaroxaban), FDA must remain focused on the proposed indication - despite the inclination to factor in the risks associated with potential off-label use, Office of Oncology Drug Products Director Richard Pazdur said